:: CLDF ::

The Diabetes Syndrome - A Collection of Conditions with Common, Interrelated Pathophysiologic Mechanisms

Int J Gen Med. 2021 Mar 18;14:923-936. doi: 10.2147/IJGM.S305156. eCollection 2021.

Amy W Rachfal¹, Struan F A Grant^2 3 4, Stanley S Schwartz^5 6

Experimental and Investigational Targeted Therapies for the Management of Fibrosis in NASH: An Update

J Exp Pharmacol. 2021 Mar 18;13:329-338. doi: 10.2147/JEP.S265286.eCollection 2021.

Tsipora M Huisman¹, Douglas T Dieterich¹, Scott L Friedman¹

Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes

Front Endocrinol (Lausanne). 2021 Mar 4;12:642432. doi: 10.3389/fendo.2021.642432.eCollection 2021.

Jacqueline Bayliss¹, Geraldine J Ooi², William De Nardo¹, Yazmin Johari Halim Shah², Magdalene K Montgomery¹, Catriona McLean³, William Kemp⁴, Stuart K Roberts⁴, Wendy A Brown², Paul R Burton², Matthew J Watt¹

The prevalence of metabolic associated fatty liver detected by FibroScan® in women with gestational diabetes in a multiethnic population

Diabetes Res Clin Pract. 2021 Mar 17;174:108757. doi: 10.1016/j.diabres.2021.108757.Online ahead of print.

Difei Deng¹, Jacob George², Dharmintra Pasupathy³, N Wah Cheung⁴

Endoplasmic Reticulum Stress and Autophagy in the Pathogenesis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Evidence and Perspectives

Curr Obes Rep. 2021 Mar 22. doi: 10.1007/s13679-021-00431-3.Online ahead of print.

Christina-Maria Flessa^1 2, Ioannis Kyrou^2 3 4, Narjes Nasiri-Ansari¹, Gregory Kaltsas⁵, Athanasios G Papavassiliou¹, Eva Kassi^6 7, Harpal S Randeva^8 9

Alternative Etiologies of Liver Disease in Children With Suspected NAFLD

Pediatrics. 2021 Mar 30;147(4):e2020009829. doi: 10.1542/peds.2020-009829.Online ahead of print.

Toshifumi Yodoshi¹, Sarah Orkin¹, Ana Catalina Arce-Clachar^1 2, Kristin Bramlage¹, Stavra A Xanthakos^1 2, Pamela L Valentino³, Marialena Mouzaki^4 2

LI-RADS v2018 major criteria: Do hepatocellular carcinomas in non-alcoholic steatohepatitis differ from those in virus-induced chronic liver disease on MRI?

Eur J Radiol. 2021 Mar 11;138:109651. doi: 10.1016/j.ejrad.2021.109651. Online ahead of print.

Maxime Barat¹, Thi Thuy Linh Nguyen², Clémence Hollande³, Jean-Baptiste Coty⁴, Christine Hoeffel⁵, Benoit Terris⁶, Anthony Dohan⁴, Vincent Mallet³, Stanislas Pol³, Philippe Soyer⁴

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Nature. 2021 Mar 24. doi: 10.1038/s41586-021-03362-0. Online ahead of print.

Dominik Pfister^1 2, Nicolás Gonzalo Núñez³, Roser Pinyol⁴, Olivier Govaere⁵, Matthias Pinter^6 7, Marta Szydlowska¹, Revant Gupta^8 9, Mengjie Qiu¹⁰, Aleksandra Deczkowska¹¹, Assaf Weiner¹¹, Florian Müller¹, Ankit Sinha^12 13, Ekaterina Friebel³, Thomas Engleitner^14 15 16, Daniela Lenggenhager¹⁷, Anja Moncsek¹⁸, Danijela Heide¹, Kristin Stirm¹, Jan Kosla¹, Eleni Kotsiliti¹, Valentina Leone^1 19, Michael Dudek²⁰, Suhail Yousuf¹⁰, Donato Inverso^21 22, Indrabahadur Singh^1 23, Ana Teijeiro²⁴, Florian Castet⁴, Carla Montironi⁴, Philipp K Haber²⁵, Dina Tiniakos^5 26, Pierre Bedossa⁵, Simon Cockell²⁷, Ramy Younes^5 28, Michele Vacca²⁹, Fabio Marra³⁰, Jörn M Schattenberg³¹, Michael Allison³², Elisabetta Bugianesi²⁸, Vlad Ratziu³³, Tiziana Pressiani³⁴, Antonio D'Alessio³⁴, Nicola Personeni^34 35, Lorenza Rimassa^34 35, Ann K Daly⁵, Bernhard Scheiner^6 7, Katharina Pomej^6 7, Martha M Kirstein^36 37, Arndt Vogel³⁶, Markus Peck-Radosavljevic³⁸, Florian Hucke³⁸, Fabian Finkelmeier³⁹, Oliver Waidmann³⁹, Jörg Trojan³⁹, Kornelius Schulze⁴⁰, Henning Wege⁴⁰, Sandra Koch⁴¹, Arndt Weinmann⁴¹, Marco Bueter⁴², Fabian Rössler⁴², Alexander Siebenhüner⁴³, Sara De Dosso⁴⁴, Jan-Philipp Mallm⁴⁵, Viktor Umansky^46 47, Manfred Jugold⁴⁸, Tom Luedde⁴⁹, Andrea Schietinger^50 51, Peter Schirmacher⁵², Brinda Emu¹, Hellmut G Augustin^21 22, Adrian Billeter⁵³, Beat Müller-Stich⁵³, Hiroto Kikuchi⁵⁴, Dan G Duda⁵⁴, Fabian Kütting⁵⁵, Dirk-Thomas Waldschmidt⁵⁵, Matthias Philip Ebert⁵⁶, Nuh Rahbari⁵⁷, Henrik E Mei⁵⁸, Axel Ronald Schulz⁵⁸, Marc Ringelhan^59 60 61, Nisar Malek⁶², Stephan Spahn⁶², Michael Bitzer⁶², Marina Ruiz de Galarreta^25 63, Amaia Lujambio^25 63 64, Jean-Francois Dufour^65 66, Thomas U Marron^25 67, Ahmed Kaseb⁶⁸, Masatoshi Kudo⁶⁹, Yi-Hsiang Huang^70 71, Nabil Djouder²⁴, Katharina Wolter^72 73, Lars Zender^72 73 74, Parice N Marche^75 76, Thomas Decaens^75 76 77, David J Pinato^78 79, Roland Rad^14 15 16, Joachim C Mertens¹⁸, Achim Weber^17 80, Kristian Unger¹⁹, Felix Meissner¹², Susanne Roth¹⁰, Zuzana Macek Jilkova^75 76 78, Manfred Claassen^8 9, Quentin M Anstee^5 81, Ido Amit¹¹, Percy Knolle²⁰, Burkhard Becher³, Josep M Llovet^82 83 84, Mathias Heikenwalder⁸⁵

Affiliations collapse

Bariatric Surgery Reduces Cancer Risk in Adults with Nonalcoholic Fatty Liver Disease and Severe Obesity

Gastroenterology. 2021 Mar 17;S0016-5085(21)00529-1. doi: 10.1053/j.gastro.2021.03.021.Online ahead of print.

Vinod K Rustgi¹, You Li², Kapil Gupta², Carlos D Minacapelli², Abhishek Bhurwal², Carolyn Catalano², Mohamed I Elsaid²

10.

The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk

Curr Diab Rep. 2021 Mar 19;21(5):15. doi: 10.1007/s11892-021-01383-7.

Cyrielle Caussy¹, Adrien Aubin², Rohit Loomba^3 4 5

11.

Sex differences in NAFLD: estrogen influence on the liver-adipose tissue crosstalk

Antioxid Redox Signal. 2021 Mar 19. doi: 10.1089/ars.2021.0044. Online ahead of print.

Andrea Morán-Costoya^1 2, Ana María Proenza^1 3 4, Magdalena Gianotti^5 3 6, Isabel Lladó^1 3 7, Adamo Valle^1 3 8

12.

Ten Thousand Points of Light - Heterogeneity Among the Stars of NASH Fibrosis

Hepatology. 2021 Mar 16.doi: 10.1002/hep.31807. Online ahead of print.

James Carter¹, Shuang Wang¹, Scott L Friedman¹

13.

The clinical impact of cirrhosis on the postoperative outcomes of patients undergoing bariatric surgery: propensity score-matched analysis of 2011-2017 US hospitals

Expert Rev Gastroenterol Hepatol. 2021 Mar 12. doi: 10.1080/17474124.2021.1902803.Online ahead of print.

David Uihwan Lee¹, Gregory Hongyuan Fan¹, David Jeffrey Hastie¹, Elyse Ann Addonizio¹, Vibhav Narayan Prakasam¹, Ryan Richard Ahern¹, Kristen Jin Seog¹, Raffi Karagozian¹

14.

Awareness of non-alcoholic steatohepatitis and treatment guidelines: What are physicians telling us?

World J Hepatol. 2021 Feb 27;13(2):233-241. doi: 10.4254/wjh.v13.i2.233.

David Hermanus Wessels¹, Zeil Rosenberg²

15.

Coronary artery disease and non-alcoholic fatty liver disease: Clinical correlation using computed tomography coronary calcium scans

JGH Open. 2021 Feb 19;5(3):390-395. doi: 10.1002/jgh3.12509. eCollection 2021 Mar.

Richard S Kirby¹, Dina Halegoua-DeMarzio²

16.

Increased adipose tissue fibrogenesis, not impaired expandability, is associated with nonalcoholic fatty liver disease

Hepatology. 2021 Mar 20. doi: 10.1002/hep.31822. Online ahead of print.

Joseph W Beals¹, Gordon I Smith¹, Mahalakshmi Shankaran², Anja Fuchs³, George G Schweitzer¹, Jun Yoshino¹, Tyler Field², Marcy Matthews², Edna Nyangau², Darya Morozov⁴, Bettina Mittendorfer¹, Marc K Hellerstein², Samuel Klein¹

17.

European 'NAFLD Preparedness Index' - Is Europe ready to meet the challenge of fatty liver disease?

JHEP Rep. 2021 Jan 21;3(2):100234. doi: 10.1016/j.jhepr.2021.100234. eCollection 2021 Apr.

Jeffrey V Lazarus¹, Adam Palayew², Patrizia Carrieri³, Mattias Ekstedt⁴, Giulio Marchesini⁵, Katja Novak⁶, Vlad Ratziu⁷, Manuel Romero-Gómez⁸, Frank Tacke⁹, Shira Zelber-Sagi¹⁰, Helena Cortez-Pinto¹¹, Quentin M Anstee^12 13

18.

Treatment candidacy for pharmacologic therapies for NASH

Clin Gastroenterol Hepatol. 2021 Mar 9;S1542-3565(21)00228-7.doi: 10.1016/j.cgh.2021.03.005. Online ahead of print.

Ian A Rowe¹, Vincent Wai-Sun Wong², Rohit Loomba³

19.

The Impact of Macronutrient Intake on Non-alcoholic Fatty Liver Disease (NAFLD): Too Much Fat, Too Much Carbohydrate, or Just Too Many Calories?

Front Nutr. 2021 Feb 16;8:640557. doi: 10.3389/fnut.2021.640557. eCollection 2021.

Theresa Hydes^1 2, Uazman Alam^1 2, Daniel J Cuthbertson^1 2

20.

Treatments for NAFLD: State of Art

Int J Mol Sci. 2021 Feb 26;22(5):2350. doi: 10.3390/ijms22052350.

Alessandro Mantovani¹, Andrea Dalbeni²

21.

The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis

Contemp Clin Trials. 2021 Feb 28;106335. doi: 10.1016/j.cct.2021.106335. Online ahead of print.

Manal F Abdelmalek¹, Edgar D Charles², Arun J Sanyal³, Stephen A Harrison⁴, Brent A Neuschwander-Tetri⁵, Zachary Goodman⁶, Richard A Ehman⁷, Morten Karsdal⁸, Atsushi Nakajima⁹, Shuyan Du¹⁰, Giridhar S Tirucherai¹⁰, George H Klinger¹⁰, Johanna Mora¹⁰, Masayuki Yamaguchi¹⁰, Diane E Shevell¹⁰, Rohit Loomba¹¹